Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Andrew Fein reiterates Kamada (NASDAQ:KMDA) with a Buy and maintains $11 price target.
Kamada also increased adjusted EBITDA guidance to $28 million to $32 million from the initial guidance of $27 million to $30 mi...
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33....
HC Wainwright & Co. analyst Andrew Fein reiterates Kamada (NASDAQ:KMDA) with a Buy and maintains $11 price target.
“Looking ahead, we anticipate continued momentum through 2024, with double-digit top- and bottom-line growth. Specifically, we ...
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.05 by 80 pe...
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...
Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed...
